Skip to main content

Table 1 Characteristics of study participants according to the presence or absence of CAD

From: Serum lipocalin-2 levels positively correlate with coronary artery disease and metabolic syndrome

Variables

Non-CAD

CAD

Total

Men

Women

Total

Men

Women

N

73

38

35

188

131

57

Age (years)

63.6 ± 9.4

62.1 ± 9.7

65.2 ± 8.8

66.8 ± 9.5a

65.7 ± 9.9b

69.3 ± 8.0c

CSI

0 (0–1)

0 (0–1)

0 (0–1)

9 (5–14)aa

10 (5–14)bb

8 (4–14)cc

BMI (kg/m2)

25.5 ± 3.7

25.4 ± 4.1

25.6 ± 3.4

24.4 ± 3.1a

24.7 ± 3.1

23.9 ± 3.0c

W (cm)

90.7 ± 10.8

92.7 ± 11.9

88.5 ± 9.0

90.3 ± 8.8

91.7 ± 8.5

87.3 ± 8.7

SBP (mmHg)

130 (120–150)

130 (120–150)

130 (120–145)

133 (120–150)

130 (120–147)

140 (128–150)

DBP (mmHg)

80 (70–87)

80 (70–88)

80 (70–86)

80 (70–84)

80 (70–84)

75 (70–82)

FPG (mmol/L)

5.38 (5.07-6.17)

5.64 (5.12-6.23)

5.31 (5.00-5.96)

5.46 (5.04-6.57)

5.44 (5.04-6.41)

5.59 (4.99-7.64)

2hPG (mmol/L)

8.17 (6.27-9.97)

9.12 (6.79-10.55)

7.17 (5.27-9.29)

8.76 (6.66-11.92)

8.77 (6.71-12.16)

8.67 (6.49-11.72)

HbA1c (%)

6.2 (5.7-6.5)

6.2 (5.6-6.5)

6.2 (5.7-6.4)

6.2 (5.8-6.9)

6.2 (5.8-6.7)

6.4 (5.8-7.2)

HOMA-IR

4.1 (2.9-5.9)

3.9 (3.1-5.4)

4.9 (2.8-6.0)

4.0 (2.8-5.9)

4.0 (2.7-5.6)

4.3 (2.9-6.8)

TC (mmol/L)

4.53 ± 1.03

4.20 ± 0.95

4.90 ± 0.99

4.31 ± 1.10

4.17 ± 1.02

4.63 ± 1.20

TG (mmol/L)

1.63 (1.04-2.30)

1.62 (1.09-2.18)

1.66 (0.88-2.44)

1.51 (1.08-2.25)

1.49 (1.04-2.14)

1.57 (1.17-2.57)

HDL-c (mmol/L)

1.07 (0.88-1.37)

0.97 (0.81-1.38)

1.26 (1.06-1.37)

1.02 (0.87-1.28)

0.96 (0.85-1.16)

1.19 (0.93-1.35)

LDL-c (mmol/L)

3.06 ± 0.86

2.85 ± 0.90

3.30 ± 0.76

2.90 ± 0.99

2.83 ± 0.93

3.08 ± 1.10

Serum adiponectin (ug/mL)

7.8 (5.7-11.5)

7.4 (5.0-10.5)

8.9 (5.8-14.2)

7.0 (4.8-11.1)

6.5 (4.4-10.6)

7.9 (6.1-13.0)

UA (μmol/L)

341.6 ± 85.2

383.0 ± 79.5

295.2 ± 66.1

342.0 ± 82.7

349.1 ± 78.1b

325.7 ± 91.0

Scr (μmol/L)

73.2 ± 18.4

83.2 ± 15.8

61.9 ± 14.2

78.0 ± 19.4

83.8 ± 17.1

64.5 ± 17.7

24hALB (mg/d)

7.8 (4.9-17.1)

8.5 (5.6-18.1)

6.6 (3.4-15.3)

7.0 (4.7-14.3)

7.1 (4.6-12.9)

6.7 (5.1-19.6)

eGFR (mL/min/1.73 m2)

92.6 ± 22.7

90.3 ± 19.7

95.2 ± 25.7

89.6 ± 22.3

89.2 ± 21.3

90.7 ± 24.9

CRP (mg/L)

1.1 (0.4-3.1)

1.0 (0.5-2.4)

1.2 (0.4-3.1)

1.1 (0.5-2.8)

1.0 (0.5-2.8)

1.2 (0.5-3.5)

Neutrophils (×109/L)

4.0 (3.1-4.7)

4.1 (3.3-5.1)

3.5 (2.6-4.5)

3.9 (3.1-4.7)

4.0 (3.3-4.7)

3.4 (2.9-4.3)

Smoking, n (%)

26 (35.6)

25 (65.8)

1 (2.9)

86 (45.7)

85 (64.9)

1 (1.8)

CAD family history, n (%)

33 (45.2)

19 (50.0)

14 (40.0)

85 (45.2)

57 (43.5)

28 (49.1)

Hypoglycemic therapy, n (%)

11 (15.1)

6 (15.8)

5 (14.3)

51 (27.1)a

31 (23.7)

20 (35.1)c

Anti-hypertensive therapy, n (%)

50 (68.5)

30 (78.9)

20 (57.1)

128 (68.1)

89 (67.9)

39 (68.4)

Lipid-lowering therapy, n (%)

11 (15.1)

6 (15.8)

5 (14.3)

62 (33.0)aa

43 (32.8)b

19 (33.3)c

  1. CSI: Coronary stenosis index; BMI: Body mass index; W: Waist circumference; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FPG: Fasting plasma glucose; 2hPG: 2 h postprandial glucose; HbA1c: Glycated hemoglobin A1c; HOMA-IR: Homeostasis model assessment index; TC: Total cholesterol; TG: Triglyceride; UA: Uric acid; Scr: Serum creatinine; 24hALB: 24 h urine albumin; eGFR: Estimated glomerular filtration rate; CRP: C-reactive protein; Neutrophils: number of neutrophils.
  2. For the total subjects: ap < 0.05, CAD vs. non-CAD; aap < 0.01, CAD vs. non-CAD; for the men subgroup: bp < 0.05, CAD vs. non-CAD, bbp < 0.01, CAD vs. non-CAD; for the women subgroup: cp < 0.05, CAD vs. non-CAD, ccp < 0.01, CAD vs. non-CAD. Data are presented as mean ± SD or median (inter-quartile range).